Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | DRD4 | P21917 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3931356 | 1.00 | SIGMAR1 (0.41) | SIGMAR1CHRM4MAOAMAOBDRD2 | |
| SCHEMBL146403 | 0.82 | KMT2A (0.45) | SIGMAR1CHRM4MAOAMAOBDRD2 | |
| SCHEMBL459129 | 0.82 | KMT2A (0.45) | SIGMAR1CHRM4MAOAMAOBDRD2 | |
| SCHEMBL146402 | 0.82 | KMT2A (0.45) | SIGMAR1CHRM4MAOAMAOBDRD2 | |
| SCHEMBL1721160 | 0.79 | SIGMAR1 (0.43) | SIGMAR1CHRM4MAOAMAOBDRD2 | |
| SCHEMBL1721155 | 0.79 | SIGMAR1 (0.43) | SIGMAR1CHRM4MAOAMAOBDRD2 | |
| SCHEMBL3921370 | 0.77 | S1PR5 (0.49) | SIGMAR1MAOBDRD2DRD4DRD3 | |
| SCHEMBL3921374 | 0.77 | S1PR5 (0.49) | SIGMAR1MAOBDRD2DRD4DRD3 | |
| SCHEMBL1721452 | 0.74 | KMT2A (0.48) | SIGMAR1MAOAMAOBDRD2DRD4 | |
| SCHEMBL146363 | 0.74 | KMT2A (0.48) | SIGMAR1MAOAMAOBDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485641-B2 | Substituted 3-amino-pyrrolidino-4-lactams | PFIZER, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20070299076-A1 | Substituted 3-Amino-Pyrrolidino-4-Lactams | PFIZER INC | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299076-A1 | Substituted 3-Amino-Pyrrolidino-4-Lactams | PRMT1, PRMT7, PRMT3 | SIGMAR1 1872/4885CHRM4 4013/4885MAOA 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.